Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;30(8):624-633.
doi: 10.1111/iju.15197. Epub 2023 Jun 12.

Mechanism and treatment for chronic antibody-mediated rejection in kidney transplant recipients

Affiliations
Review

Mechanism and treatment for chronic antibody-mediated rejection in kidney transplant recipients

Hajime Sasaki et al. Int J Urol. 2023 Aug.

Abstract

Chronic antibody-mediated rejection of kidney transplantation is a major cause of late-stage graft loss. Donor-specific antibodies are the main cause of antibody-mediated rejection; in particular, de novo donor-specific antibodies are a risk factor for chronic active antibody-mediated rejection. The level of de novo donor-specific antibodies tends to increase with time throughout long-term graft survival. Donor-specific antibodies induce humoral rejection through complement activation, which results in tissue injury and coagulation. Additionally, complement activation promotes the migration of inflammatory cells through the innate immune response, causing endothelial injury. This inflammatory response may cause persistent glomerulitis and peritubular capillaritis, leading to fixed pathological lesions that impair graft function. No treatment has been established for chronic antibody-mediated rejection, a condition in which antibody-mediated rejection becomes irreversible. Thus, antibody-mediated rejection must be detected and treated while it is still reversible. In this review, we discuss the development of de novo donor-specific antibodies and the mechanisms leading to chronic antibody-mediated rejection and summarize the current treatment options and the latest biomarkers for detecting chronic antibody-mediated rejection at an earlier stage.

Keywords: antibody-mediated rejection; biomarkers; donor-specific antibody; kidney transplantation; transplant glomerulopathy.

PubMed Disclaimer

References

REFERENCES

    1. Wakasugi M, Narita I. Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. Nephrology (Carlton). 2023;28:119-29.
    1. Yagisawa TMM, Ichimaru N, Morita K, Nakamura M, Hotta K, Kenmochi T, et al. Trends of kidney transplantation in Japan in 2018: data from the kidney transplant registry. Ren Replace Ther. 2019;5:3.
    1. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9:2520-31.
    1. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388-99.
    1. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation. 2005;80:1194-7.

LinkOut - more resources